Ultragenyx Pharmaceutical | RARE - Ebitda


Ultragenyx Pharmaceutical reported $-156.79M in EBITDA for its fiscal quarter ending in September of 2025.





Ebitda Change Date
Acadia Pharmaceuticals USD 35.76M 447K Sep/2025
Agios Pharmaceuticals USD -115.49M 10.3M Sep/2025
Alnylam Pharmaceuticals USD 145.22M 236.56M Dec/2025
BioCryst Pharmaceuticals USD 51.7M 30.14M Sep/2025
BioMarin Pharmaceutical USD -24.17M 18.91M Dec/2025
Esperion Therapeutics USD -9.93M 24.99M Sep/2025
Immunic USD -22.78M 753K Jun/2024
Insmed USD -314.19M 31.48M Dec/2025
Ionis Pharmaceuticals USD -157.12M 307.36M Sep/2025
Karyopharm Therapeutics USD -26.2M 1.83M Sep/2024
Kyowa Hakko Kirin JPY 45.74B 13.46B Dec/2025
MacroGenics USD 21.95M 55.39M Sep/2025
Moderna USD -790M 582M Dec/2025
Neurocrine Biosciences USD 218.4M 28.3M Dec/2025
PTC Therapeutics USD 20.63M 53.74M Sep/2025
Puma Biotechnology USD 729K 11.36M Jun/2024
Regeneron Pharmaceuticals USD 1.92B 261.9M Sep/2025
Sarepta Therapeutics USD -168.03M 294.45M Sep/2025
Ultragenyx Pharmaceutical USD -156.79M 65.44M Sep/2025
Vertex Pharmaceuticals USD 1.44B 100.4M Sep/2025
Xoma USD 2.52M 7.98M Jun/2024